BioIntel is now The Catalyst Brief.
The Catalyst Brief
Coverage

Regulatory & Policy

FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.

Page 43 of 43

Archive

New U.S. Dietary Guidelines Stir Debate Amid Panel's Industry Financial TiesJan 7, 2026

New U.S. Dietary Guidelines Stir Debate Amid Panel's Industry Financial Ties

The latest dietary guidelines recommend increased protein and dairy consumption while reducing sugar and processed food intake. However, scrutiny arises due to the advisory panel's financial ties to industries that benefit from these changes. This controversy comes amid criticism from figures like Robert F. Kennedy Jr. regarding corporate influence in public health policies.

The Catalyst Brief
FDA Eases Oversight on AI-Enabled Devices and Wearables to Promote InnovationJan 6, 2026

FDA Eases Oversight on AI-Enabled Devices and Wearables to Promote Innovation

In a significant policy shift aimed at accelerating innovation and access, the FDA will reduce its regulatory burden on AI-powered and wearable health technology. This move reflects a strategic decision to facilitate the expansion of AI use in healthcare while balancing safety and efficacy.

The Catalyst Brief
Federal Health Officials Slash Childhood Vaccine RecommendationsJan 6, 2026

Federal Health Officials Slash Childhood Vaccine Recommendations

The number of recommended childhood vaccinations has been significantly trimmed, raising concerns among health experts about the new vaccine schedule's impact on children's near- and long-term health. This major policy change alters the longstanding immunization framework.

The Catalyst Brief

Other beats

AI in Drug Discovery

Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.

Biopharmaceutical Industry

Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.

Biotech Innovation

Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.

Healthcare Investment

Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.

Medical Technology

Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.